Appili Therapeutics Inc. (APLI.TO) TSX

0.04

-0.005(-12.50%)

Updated at October 02 03:27PM

Currency In CAD

Appili Therapeutics Inc.

Address

#21-1344 Summer Street

Halifax, NS B3H 0A8

Canada

Phone

902 442 4655

Sector

Healthcare

Industry

Biotechnology

Employees

8

First IPO Date

June 25, 2019

Key Executives

NameTitlePayYear Born
Dr. Donald D. Cilla Jr., M.B.A., PharmdChief Executive Officer, President & Director588,595N/A
Dr. Carl Gelhaus Ph.D.Director of Non-Clinical Research296,657N/A
Mr. Arthur BaranDirector of New Product Development308,701N/A
Dr. Gary S. Nabors Ph.D.Chief Development Officer540,011N/A

Description

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.